Beneath a solid fourth-quarter earnings season, there’s a worrisome development that may put a dent in the bull case for US ...
In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback